title: Salvage therapy with amprenavir and ritonavir: prospective study in 17 heavily pretreated patients.
abstract: OBJECTIVE
  To evaluate the safety profile and efficacy of salvage regimens containing amprenavir (APV) 600 mg twice daily and ritonavir (RTV) 200 mg twice daily.
  
  
  METHODS
  Prospective, single-center study.
  
  
  METHODS
  The patient database of the department of infectious diseases was screened for patients who had failed at least two successive three-drug combinations. These patients were proposed to take APV and RTV in association with two to four other drugs. They were followed monthly for 6 months.
  
  
  RESULTS
  Seventeen patients were included. They had been previously treated for 70 +/- 23 months. At baseline, viral load (VL) was 4.86 +/- 0.98 log10 copies/mL and CD4 187 +/- 145 10(6)/L. On week 24, using intent-to-treat analysis, VL decreased to 2.95 +/- 1.59 log10 copies/mL and CD4 increased to 365 +/- 210 10(6)/L. Nine patients (53%) had a VL < 2.3 log10 copies/mL. The most common adverse events were grade 1 or 2 diarrhea and an increase of cholesterol and triglyceride levels. Mean APV trough concentration was 1727 +/- 1749 ng/mL on week 24.
  
  
  CONCLUSIONS
  These data show that the combination of low-dose RTV and reduced doses of APV is safe. This combination can be added to nonnucleoside analogs.
authors.affiliation: Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier et Universitaire de Rennes, Rennes, France. Cedric.Arvieux@chu-rennes.fr
authors.forename: Cédric
authors.initials: C
authors.lastname: Arvieux
authors.forename: Pierre
authors.initials: P
authors.lastname: Tattevin
authors.forename: Faouzi M
authors.initials: FM
authors.lastname: Souala
authors.forename: Philippe
authors.initials: P
authors.lastname: Jaccard
authors.forename: Annick
authors.initials: A
authors.lastname: Ruffault
authors.forename: Danielle
authors.initials: D
authors.lastname: Bentué-Ferrer
authors.forename: Olivier
authors.initials: O
authors.lastname: Tribut
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Chapplain
authors.forename: Mathieu
authors.initials: M
authors.lastname: Dupont
authors.forename: Cécile
authors.initials: C
authors.lastname: Bouvier
authors.forename: Christian
authors.initials: C
authors.lastname: Michelet
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D002219:Carbamates; D024882:Drug Resistance, Viral / Q000235:genetics; D004359:Drug Therapy, Combination; D005260:Female; D005663:Furans; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D010641:Phenotype; D011446:Prospective Studies; D019438:Ritonavir / Q000009:adverse effects / Q000627:therapeutic use*; D016879:Salvage Therapy; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D013449:Sulfonamides; C095108:amprenavir; D019438:Ritonavir